NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-11-03 18:16இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Privi Speciality Reports Record Q2 Total Income of ₹773 Cr, Interim Dividend of ₹5/Share
Privi Speciality Chemicals filed its Q2 & H1 FY27 earnings call transcript, highlighting its highest ever quarterly total income of ₹773.16 crore, up 13.9% YoY. Operating profit (EBITDA) reached ₹212.49 crore with a 27.48% margin, while PAT rose 24.61% YoY to ₹117.03 crore. The company completed its Phase 1 capacity expansion to 54,000 MTPA as of September 30, 2026, and declared its first-ever interim dividend of ₹5 per share. Management reiterated its '5K:1K' vision, targeting ₹5,000 crore revenue and ₹1,000 crore EBITDA by 2030 through three planned capex phases expected to generate ~₹1,900 crore incremental revenue.
உச்சம் நம்பிக்கை
என்ன மாறியதுPrivi published the earnings call transcript detailing its record Q2 FY27 operational and financial metrics, completion of Phase 1 capex, and future expansion milestones.
ஏன் இது முக்கியம்Demonstrates robust operating momentum, expanding capacity to 54,000 MTPA, and provides visibility into the 2030 roadmap targeting ₹5,000 crore revenue.
📅 குறுகிய காலம்Market sentiment should stay supported following record profitability and the maiden interim dividend payout.
📈 நீண்ட காலம்The completion of Phase 1 capex and ongoing pilot-scale commercialization for specialty molecules reinforce the runway toward the company's 2030 targets.
⚠ அபாய எச்சரிக்கைகள்
Exposure to volatility in crude derivative feedstock prices and shipping/freight costs
Working capital intensity inherent in specialty aroma chemical supply chains
👀 கவனிக்க வேண்டியவை
Track the commercial ramp-up and margin delivery from the newly operational 6,000 MTPA capacity, along with customer qualification cycles for new molecules (maltol, ethyl maltol, cyclopentanone).
Privi Speciality Q2 FY27 Total Income Up 13.9% to ₹773.16 Cr; Targets ₹5,000 Cr Sales by FY30
Privi Speciality Chemicals released its investor presentation for Q2 & H1 FY27, reporting consolidated Q2 total income of ₹773.16 Cr, up 13.9% YoY, and EBITDA of ₹212.49 Cr, up 16.7% YoY with a margin of 27.5%. Net profit attributable to the company grew 24.6% YoY to ₹117.03 Cr. Balance sheet deleveraging continued with Net Debt to Equity improving to 0.51x (from 0.62x at FY26) and Net Debt to EBITDA down to 1.07x. Management reaffirmed its '5k | 1k' roadmap targeting ₹5,000 Cr revenue and ₹1,000+ Cr EBITDA by FY29-30, with ongoing expansion projects slated for commercial operations in H2 2028.
உச்சம் நம்பிக்கை
என்ன மாறியதுPublished Q2 & H1 FY27 investor presentation showing double-digit revenue and PAT growth alongside ongoing balance sheet deleveraging.
ஏன் இது முக்கியம்Demonstrates sustained margin expansion (EBITDA margin at 27.5%) and healthy cash generation, keeping the company on course toward its 2x growth goal (₹5,000 Cr revenue) by FY30.
Q2 FY27 Total Income: ₹773.16 கோடிQ2 FY27 EBITDA: ₹212.49 கோடிQ2 FY27 PAT (Attributable): ₹117.03 கோடிNet Debt to Equity: 0.51xFY30 Revenue Target: ₹5,000 கோடி
📅 குறுகிய காலம்Likely to support market sentiment as earnings growth continues at >20% YoY, with finance costs falling 21.3% YoY to ₹16.90 Cr due to debt reduction.
📈 நீண்ட காலம்Structural tailwinds persist as high-margin specialty chemicals, the PRIGIV JV ramp-up, and biotechnology integration (PFSPL/PBPL amalgamation) drive progress toward the ₹5,000 Cr revenue vision.
⚠ அபாய எச்சரிக்கைகள்
Raw material price volatility tied to crude derivatives
Capex execution risk with major expansion projects scheduled for H2 2028
👀 கவனிக்க வேண்டியவை
Track the execution timeline of current capacity additions scheduled for H2 2028, and monitor commentary during the earnings call regarding product ramp-up in the PRIGIV JV.
Privi Speciality Declares ₹5/Share Interim Dividend; Approves ₹2.97 Cr Green Energy Investment
Privi Speciality Chemicals declared a first interim dividend of ₹5 per equity share (face value ₹10) for FY 2026-27, setting the record date as November 04, 2026, and payout by November 25, 2026. The board also approved an investment limit of ₹2.97 crore in Opera Dwarka Projects Private Limited for a captive Wind Solar Hybrid project in Gujarat (Unit VI). Additionally, the company noted that shareholders approved the Scheme of Amalgamation at the NCLT-convened meeting on October 27, 2026. Standalone and consolidated H1/Q2 FY27 unaudited results were adopted with an unmodified review conclusion from auditor B S R & Co. LLP.
உச்சம் நம்பிக்கை
என்ன மாறியதுPrivi Speciality announced a ₹5/share interim dividend, greenlit a ₹2.97 crore renewable power investment, and confirmed shareholder clearance of its amalgamation scheme.
ஏன் இது முக்கியம்The dividend signals continued shareholder payout, while the hybrid renewable energy investment supports power cost optimization for Unit VI.
Interim dividend per share: Rs. 5Dividend record date: நவம்பர் 04, 2026Investment in hybrid power project: Rs. 2,97,00,000H1 Operating cash flow: Rs. 360.26 CrInvestment vs Net worth: ~0.21%
📅 குறுகிய காலம்Ex-dividend adjustment will occur around November 04, 2026, with dividend payout scheduled by November 25, 2026.
📈 நீண்ட காலம்Limited direct impact from the minor ₹2.97 crore renewable energy equity check, though progress on the Scheme of Amalgamation remains structurally relevant.
⚠ அபாய எச்சரிக்கைகள்
Final approval and sanction from NCLT required for the Scheme of Amalgamation.
👀 கவனிக்க வேண்டியவை
Track the upcoming dividend record date of November 04, 2026, and monitor subsequent NCLT filings for the final sanction of the Scheme of Amalgamation.
Privi Speciality Shareholders Approve Amalgamation Scheme with 89.72% Majority
Privi Speciality Chemicals Limited announced that shareholders have approved the Scheme of Amalgamation of Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited with the company. The resolution was passed at an NCLT-convened meeting on October 27, 2026, with an overall 89.72% vote in favor. Notably, 82.87% of voting public institutional shareholders opposed the resolution, whereas 100% of promoter votes and 99.96% of voting public non-institutional shares voted in favor. The amalgamation proceeds to the next phase of NCLT approvals.
உச்சம் நம்பிக்கை
என்ன மாறியதுShareholders formally approved the Scheme of Amalgamation to merge Privi Fine Sciences Pvt Ltd and Privi Biotechnologies Pvt Ltd into Privi Speciality Chemicals.
ஏன் இது முக்கியம்Consolidates group biotechnology and fine sciences operations into the listed parent company, though strong institutional pushback (82.87% against) signals market scrutiny over related-party deal terms.
📅 குறுகிய காலம்Approval ensures the corporate restructuring stays on track without delays from the court-convened meeting stage.
📈 நீண்ட காலம்Structural integration of fine sciences and biotechnologies may consolidate corporate structure, though business synergy realization will take several quarters.
⚠ அபாய எச்சரிக்கைகள்
High institutional dissent (82.87% of voting institutions voted against)
Related-party transaction execution risks
👀 கவனிக்க வேண்டியவை
Track the upcoming final approval and hearing schedule at the NCLT Mumbai bench, alongside filings on the effective date and integration timeline.
Privi Speciality Chemicals Sets Oct 27 NCLT Shareholder Meet for Two-Entity Amalgamation
Privi Speciality Chemicals Limited has issued a notice convening an equity shareholders' meeting on October 27, 2026, as directed by the NCLT Mumbai Bench. The meeting is to consider and approve the Scheme of Amalgamation of Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited with the company. NCLT had earlier dispensed with meetings of creditors and transferor company members via its order dated September 7, 2026. The Appointed Date for the merger is fixed as October 1, 2025.
உச்சம் நம்பிக்கை
என்ன மாறியதுNCLT Mumbai has directed Privi Speciality Chemicals to convene a meeting of its equity shareholders on October 27, 2026, to vote on the amalgamation scheme.
ஏன் இது முக்கியம்The amalgamation consolidates related group entities to optimize operational infrastructure, streamline corporate structure, and integrate value chains in aroma and specialty chemicals.
Shareholder Meeting Date: 27th அக்டோபர், 2026Amalgamation Appointed Date: 01.10.2025NCLT Order Date: 7th செப்டம்பர், 2026Subsidiary Turnover (Privi Bio FY26): ₹681.51 லட்சம்
📅 குறுகிய காலம்Routine corporate and regulatory procedural step; share price impact is expected to remain muted pending voting outcomes.
📈 நீண்ட காலம்Will eliminate corporate redundancies and vertically integrate chemical manufacturing operations upon final sanction by NCLT.
⚠ அபாய எச்சரிக்கைகள்
Shareholder approval risk
NCLT final sanction timeline delays
👀 கவனிக்க வேண்டியவை
Track the outcome of the October 27, 2026 shareholder vote and the subsequent final approval petition timeline before NCLT Mumbai.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Privi Speciality Convenes NCLT-Ordered Shareholder Meeting on Oct 27, 2026 for Amalgamation
Privi Speciality Chemicals Limited has issued a notice convening a meeting of equity shareholders on October 27, 2026, pursuant to NCLT Mumbai orders dated September 7, 2026. The meeting is called to approve the proposed Scheme of Amalgamation of Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited with the company. Remote e-voting runs from October 22, 2026, to October 26, 2026, with an eligibility cut-off date of October 20, 2026. This formalizes the group's corporate restructuring process to integrate fine sciences and biotech operations.
உச்சம் நம்பிக்கை
என்ன மாறியதுPrivi Speciality Chemicals has formally scheduled an NCLT-convened shareholder meeting for October 27, 2026, to vote on the merger of two group entities.
ஏன் இது முக்கியம்The merger simplifies group structure and consolidates related businesses (Privi Fine Sciences and Privi Biotechnologies) into the listed parent company.
Meeting Date: அக்டோபர் 27, 2026E-voting cut-off date: அக்டோபர் 20, 2026NCLT Order Date: 7th செப்டம்பர், 2026
📅 குறுகிய காலம்Procedural milestone in the merger process; shareholder approval is the immediate operational hurdle over the next month.
📈 நீண்ட காலம்Once sanctioned by NCLT, the amalgamation should streamline operational synergies and corporate structure within the specialty chemicals and biotechnology verticals.
⚠ அபாய எச்சரிக்கைகள்
Shareholder rejection risk
Delay in regulatory and final NCLT court approvals
👀 கவனிக்க வேண்டியவை
Track shareholder voting results following the October 27, 2026 meeting and subsequent final NCLT sanction orders to gauge completion timelines for the amalgamation.
20% Revenue Growth in Q1 FY27; Capacity Expansion to 54,000 MTPA Nears Completion
Privi Speciality Chemicals reported a strong start to FY27 with total income rising 20.01% YoY to Rs 681.42 Cr. The company maintained resilient EBITDA margins at 24.58%, supported by volume growth and price increases. A key milestone is the imminent commercialization of Phase-1 capacity expansion, increasing total capacity from 48,000 to 54,000 MTPA. Additionally, the PRIGIV JV is scaling up with a planned Rs 50 Cr equity infusion to support 42 exclusive products for Givaudan.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has moved from planning to the final stages of its Phase-1 capacity expansion and has officially filed the merger scheme with NCLT following stock exchange approvals.
ஏன் இது முக்கியம்The expansion and sustained 25% margins demonstrate strong execution in a volatile chemical market, while the PRIGIV JV provides high-margin, exclusive revenue streams from a global leader like Givaudan.
Q1 Total Income: Rs 681.42 கோடிEBITDA லாப வரம்பு: 24.58%Target Capacity: 54,000 MTPAJV Equity Infusion: Rs 50 கோடிQ1 PAT Growth: 35.37%
📅 குறுகிய காலம்The stock may react positively to the margin resilience and the nearing completion of the Phase-1 capacity expansion, which provides immediate volume growth visibility.
📈 நீண்ட காலம்The '5K, 1K' vision (Rs 5,000 Cr revenue) and the introduction of 10 advanced specialty products like Maltol suggest a structural shift towards higher-value chemistry and larger scale.
⚠ அபாய எச்சரிக்கைகள்
Volatility in crude-derivative input costs
Geopolitical risks affecting global supply chains
Execution risk for Phase 2 and 3 expansion projects
👀 கவனிக்க வேண்டியவை
Investors should monitor the exact commercialization date of the 6,000 MTPA capacity addition and the progress of the NCLT merger process for group entities, expected to conclude within FY27.
36% PAT Growth in Q1 FY27; Privi Speciality Reaffirms Rs 5,000 Cr Revenue Vision
Privi Speciality Chemicals reported a strong start to FY27, with Q1 total income rising 20.01% YoY to Rs 681.42 Cr. Net Profit (PAT) surged 35.97% YoY to Rs 84.21 Cr, driven by broad-based demand and operational efficiencies. Despite a one-off fire incident at a warehouse costing Rs 2.78 Cr (impacting margins by 42 bps), EBITDA margins remained robust at 24.58%. The company is aggressively pursuing its '5K, 1K' vision, targeting Rs 5,000 Cr revenue and Rs 1,000 Cr EBITDA by FY29-30.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported strong Q1 FY27 results and provided an updated roadmap for its '5K, 1K' vision, indicating a clear path to doubling revenue over the next 3-4 years.
ஏன் இது முக்கியம்The results demonstrate strong operational leverage and the ability to maintain margins despite external shocks (fire incident). The improving debt-to-EBITDA ratio and ROCE indicate a strengthening balance sheet and efficient capital allocation.
Q1 FY27 Revenue: Rs 681.42 கோடிQ1 வருவாய் vs TTM வருவாய்: 26.57%EBITDA லாப வரம்பு: 24.58%Net Debt to EBITDA: 1.29xVision 2030 Revenue Target: Rs 5,000 கோடிFire Loss Impact: Rs 2.78 கோடி
📅 குறுகிய காலம்The stock is likely to react positively to the strong earnings growth and margin expansion, reflecting healthy demand in the aroma chemicals segment.
📈 நீண்ட காலம்The structural shift towards high-end speciality molecules and the Givaudan partnership (PRIGIV) position the company for sustained growth towards its FY30 targets.
⚠ அபாய எச்சரிக்கைகள்
One-off fire loss at warehouse
Volatility in crude-derivative raw material prices
Execution risk for expansion projects slated for 2028
👀 கவனிக்க வேண்டியவை
Monitor the execution of the PRIGIV JV and the progress of expansion projects slated for commercial operations in H2 2028. Investors should also track the proposed amalgamation with Privi Fine Sciences for potential synergy benefits.
Privi Speciality Files Amalgamation Scheme with NCLT; Recommends ₹10 Final Dividend
Privi Speciality Chemicals has formally filed its Scheme of Amalgamation with the NCLT Mumbai Bench as of June 25, 2026, to merge two subsidiaries into the parent entity. The Board also approved the Q1 FY27 financial results and reiterated a final dividend recommendation of ₹10 per share for FY26. The total dividend payout of ₹39.06 Cr represents approximately 12.3% of the company's TTM PAT of ₹316 Cr. This move follows the receipt of observation letters from NSE and BSE in early May 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has progressed from receiving exchange observations to the legal filing stage with the NCLT for its internal corporate restructuring.
ஏன் இது முக்கியம்The amalgamation of subsidiaries is intended to simplify the corporate structure and potentially streamline operations within its core Aroma Chemicals segment.
Final Dividend: ₹10 per shareTotal Dividend Payout: ₹39.06 கோடிDividend vs TTM PAT: ~12.3%NCLT Filing Date: ஜூன் 25, 2026
📅 குறுகிய காலம்The stock may see minor interest due to the dividend recommendation, though the market will focus on the specific Q1 FY27 performance figures once fully analyzed.
📈 நீண்ட காலம்The structural consolidation via amalgamation and the '5K, 1K' vision (targeting ₹5,000 Cr revenue) remain the key long-term value drivers.
⚠ அபாய எச்சரிக்கைகள்
Regulatory and legal delays in the NCLT approval process for the amalgamation
👀 கவனிக்க வேண்டியவை
Monitor the NCLT approval timeline for the merger and the upcoming 41st Annual General Meeting for the final dividend approval and record date.
Privi Speciality Chemicals Q1 FY27 Results; Amalgamation Filed with NCLT
Privi Speciality Chemicals approved its unaudited Q1 FY27 results for the period ended June 30, 2026. The company has formally filed its Scheme of Amalgamation for Privi Fine Sciences and Privi Biotechnologies with the NCLT Mumbai Bench as of June 25, 2026. A final dividend of Rs 10 per share for FY26, totaling Rs 39.06 Cr, is pending shareholder approval. The company continues to pursue its '5K, 1K' vision, targeting Rs 5,000 Cr revenue and Rs 1,000 Cr EBITDA over the next 3-4 years.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has progressed its internal merger from the regulatory observation stage to a formal NCLT filing.
ஏன் இது முக்கியம்The amalgamation of biotech and fine science arms into the main entity simplifies the corporate structure and aligns with the long-term goal of reaching Rs 5,000 Cr in revenue.
Final Dividend: Rs 10 per shareTotal Dividend Outlay: Rs 39.06 கோடிDividend vs TTM PAT: ~12.3%NCLT Filing Date: ஜூன் 25, 2026Target Capacity: 54,000 MTPA
📅 குறுகிய காலம்The stock may see neutral to range-bound movement as the market digests the Q1 earnings performance and the progress of the merger.
📈 நீண்ட காலம்Structural growth is tied to the successful integration of the merged entities and the realization of the '5K, 1K' vision through the Givaudan partnership.
⚠ அபாய எச்சரிக்கைகள்
Volatility in crude oil derivative prices impacting input costs
Large working capital requirements
Regulatory delays in NCLT approval for the amalgamation
👀 கவனிக்க வேண்டியவை
Monitor the NCLT approval timeline for the amalgamation and the execution of the PRIGIV JV, which is a key driver for the company's high-end product expansion.
₹300 Cr Term Loan Assigned [ICRA]AA (Stable) Rating by ICRA
ICRA Limited has assigned a new long-term rating of [ICRA]AA with a Stable outlook to Privi Speciality Chemicals' ₹300 crore term loan from ICICI Bank. This rated amount represents approximately 41% of the company's current total debt of ₹729 crore and 11.7% of its TTM revenue. The high credit rating reflects the company's strong market position as India's leading aroma chemical manufacturer and its strategic partnership with Givaudan. This assignment provides a solid credit foundation as the company pursues its '5K, 1K' vision of reaching ₹5,000 crore in revenue.
உச்சம் நம்பிக்கை
என்ன மாறியதுICRA has formally assigned a high-grade [ICRA]AA rating to a new ₹300 crore term loan facility.
ஏன் இது முக்கியம்A high credit rating (AA) confirms the company's financial stability and operational strength, ensuring continued access to low-cost capital for its capital-intensive expansion plans.
Rated Term Loan Amount: ₹300 கோடிAssigned Rating: AAOutlook: StableLoan vs Existing Debt: ~41.1%Loan vs TTM Revenue: ~11.7%
📅 குறுகிய காலம்The news is likely to be viewed positively by the market as it validates the company's creditworthiness and financial health.
📈 நீண்ட காலம்The AA rating supports the company's long-term '5K, 1K' vision by providing the necessary credit profile to fund large-scale expansions and strategic joint ventures like PRIGIV.
⚠ அபாய எச்சரிக்கைகள்
Increased debt levels if the loan is fully drawn
Sensitivity to interest rate cycles despite high rating
👀 கவனிக்க வேண்டியவை
Monitor the company's interest expense in future quarters to see if this high credit rating translates into lower borrowing costs. Investors should also track the utilization of this ₹300 crore loan toward the planned capacity expansion to 54,000 MTPA by January 2026.
Privi Speciality Chemicals FY26 PAT Surges 75% to ₹327.5 Cr; Guides for 20% Growth in FY27
Privi Speciality Chemicals delivered a robust performance in FY26, with revenue growing 21.7% to ₹2,582.9 crore and PAT surging 75.2% to ₹327.5 crore. The company maintained strong EBITDA margins of 25.8% and achieved a healthy ROCE of 22.4%. Management has guided for a 20% growth in the coming year and aims to double revenue to ₹5,000 crore within 3-4 years. Additionally, the PRIGIV joint venture turned profitable in Q4, and the company announced a dividend of ₹10 per share.
முக்கிய அம்சங்கள்
FY26 Revenue increased by 21.73% YoY to ₹2,582.92 crore, driven by volume growth and improved product mix.Net Profit (PAT) for FY26 jumped 75.16% to ₹327.54 crore, with EBITDA margins expanding to 25.76%.The Board recommended a dividend of ₹10 per share (100% of face value) following strong cash flow generation.Phase 1 capex expansion to 54,000 MTPA is on track for completion by June 30, 2026.Management targets ₹5,000 crore revenue and ₹1,000 crore+ EBITDA over the next 3-4 years, representing a 2x growth.
👀 கவனிக்க வேண்டியவை
Investors should take note of the strong margin profile and the upcoming capacity expansion as key catalysts for sustained growth. The stock remains attractive given the management's clear roadmap to double revenue and the improving profitability of the Givaudan JV.
Privi Speciality Chemicals FY26 PAT Surges 75% to ₹327.5 Cr; EBITDA Margins Expand to 25.8%
Privi Speciality Chemicals reported a robust performance for FY26, with total income growing 21.7% YoY to ₹2,582.92 crore. Profit After Tax (PAT) witnessed a significant jump of 75.2% to ₹327.54 crore, driven by volume growth and a superior product mix. The company successfully reduced its net debt by ₹113 crore, resulting in a Net Debt to Equity ratio of 0.62x. Notably, the PRIGIV JV with Givaudan turned PAT positive in Q4 FY26 and received a ₹180 crore interest-free trade advance to further deleverage the balance sheet.
முக்கிய அம்சங்கள்
FY26 Revenue increased 21.7% YoY to ₹2,582.92 crore with EBITDA growing 40.3% to ₹665.45 crore.EBITDA margins expanded by 342 bps to 25.8% for the full year FY26.Net Debt reduced from ₹1,064.96 crore to ₹886.77 crore, improving the Net Debt/EBITDA ratio to 1.33x.Return on Capital Employed (ROCE) and Return on Equity (ROE) improved significantly to 22.2% and 24.8% respectively.The PRIGIV JV achieved a milestone by turning PAT positive in Q4 FY26.
👀 கவனிக்க வேண்டியவை
Investors should maintain a positive outlook given the strong margin expansion, debt reduction, and the strategic turnaround of the Givaudan JV. The company's progress toward its '5K:1K' vision (₹5,000 Cr revenue, ₹1,000 Cr EBITDA) suggests continued growth potential.
Privi Speciality Chemicals has announced its audited financial results for the fiscal year ended March 31, 2026. The Board recommended a final dividend of Rs 10 per share (100% of face value), rewarding shareholders for the fiscal year. Key management personnel, including Executive Director Bhaktavatsala Rao Doppalapudi, have been re-appointed for a three-year term to ensure leadership stability. The company has set July 31, 2026, as the record date for dividend payments, which will be finalized following the AGM on August 7, 2026.
முக்கிய அம்சங்கள்
Recommended a final dividend of Rs 10 per equity share (100% of face value) for FY 2025-26.Approved audited standalone and consolidated financial results for the full year ending March 31, 2026.Re-appointed Mr. Bhaktavatsala Rao Doppalapudi as Executive Director for a 3-year term starting August 13, 2026.Fixed July 31, 2026, as the record date for determining dividend entitlement.The 41st Annual General Meeting (AGM) is scheduled for August 7, 2026.
👀 கவனிக்க வேண்டியவை
Existing shareholders should hold the stock until the record date of July 31, 2026, to benefit from the 100% dividend payout. The management continuity is a positive sign for long-term strategic execution.
Privi Speciality Chemicals Declares Rs 10 Dividend; Sets July 31, 2026 as Record Date
Privi Speciality Chemicals Limited has recommended a final dividend of Rs. 10 per equity share (100% of face value) for the financial year 2025-26. The company has fixed July 31, 2026, as the record date to determine the eligibility of shareholders for this payout. The board also approved the audited financial results for the year ended March 31, 2026, and scheduled the 41st Annual General Meeting for August 7, 2026. Additionally, the board approved the re-appointment of Mr. Bhaktavatsala Rao Doppalapudi as Executive Director for a three-year term.
முக்கிய அம்சங்கள்
Recommended a final dividend of Rs. 10 per equity share (100% of face value) for FY 2025-26.Fixed July 31, 2026, as the Record Date for dividend entitlement.The 41st Annual General Meeting (AGM) is scheduled to be held on August 7, 2026.Re-appointed Mr. Bhaktavatsala Rao Doppalapudi as Executive Director for 3 years effective August 13, 2026.Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they hold the stock prior to the ex-dividend date, which will be shortly before the July 31 record date. Review the full FY26 earnings report to assess the company's growth trajectory alongside the dividend payout.
Privi Speciality Chemicals Re-appoints Director, Recommends ₹10 Final Dividend
Privi Speciality Chemicals has recommended a final dividend of ₹10 per share (100% of face value) for FY 2025-26. The Board also approved the re-appointment of Mr. Bhaktavatsala Rao Doppalapudi as Executive Director for a three-year term starting August 2026. Financially, the company's standalone non-current assets grew to ₹1,39,006.99 Lakhs from ₹1,17,952.94 Lakhs year-on-year. The record date for the dividend is set for July 31, 2026, with the AGM scheduled for August 7, 2026.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹10 per equity share (100% of face value) for FY 2025-26.Re-appointed Mr. Bhaktavatsala Rao Doppalapudi as Executive Director for 3 years effective August 13, 2026.Standalone non-current assets increased by approximately 17.8% YoY to ₹1,39,006.99 Lakhs.Record date for dividend entitlement is fixed as July 31, 2026, with payment within 30 days of the AGM.
👀 கவனிக்க வேண்டியவை
Investors should maintain their positions to qualify for the ₹10 dividend before the July 31 record date. The re-appointment of key management indicates operational continuity which is a positive signal for long-term stability.
Privi Speciality Chemicals Gets BSE No-Objection for Merger with Two Group Entities
Privi Speciality Chemicals Limited (PSCL) has received a 'No Objection' observation letter from BSE Limited regarding its proposed Scheme of Amalgamation. The merger involves absorbing Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited into PSCL. This follows a previous clearance from the National Stock Exchange (NSE), marking a significant step in the regulatory approval process. The consolidation, initially approved by the Board in December 2025, aims to streamline the group's speciality chemicals and biotechnology operations.
முக்கிய அம்சங்கள்
Received 'No Objection' observation letter from BSE Limited on May 06, 2026.Proposed merger involves three entities: PSCL (Transferee), PFSPL (Transferor 1), and PBPL (Transferor 2).Company has now secured clearances from both major stock exchanges (NSE and BSE).The Scheme of Amalgamation was originally approved by the Board on December 19, 2025.Final execution remains subject to NCLT and other statutory/creditor approvals.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive regulatory milestone that brings the company closer to operational consolidation. Monitor future announcements regarding NCLT approval timelines and the potential impact on the company's consolidated financial profile.
Privi Speciality Chemicals Receives NSE No-Objection for Amalgamation Scheme
Privi Speciality Chemicals Limited (PSCL) has received a 'No Objection' observation letter from the National Stock Exchange of India (NSE) regarding its proposed scheme of amalgamation. The scheme involves merging two entities, Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited, into PSCL. This follows the initial board approval granted on December 19, 2025, and marks a significant step in the regulatory approval process. While NSE has cleared the proposal, the company is still awaiting a similar observation letter from the BSE.
முக்கிய அம்சங்கள்
Received 'No Objection' observation letter from NSE on May 05, 2026Scheme involves the merger of Privi Fine Sciences and Privi Biotechnologies into PSCLInitial board approval for the consolidation was granted on December 19, 2025Observation letter from BSE is currently awaited to proceed with the next stages of the merger
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward corporate consolidation and monitor for the upcoming BSE approval and NCLT filings. The merger is expected to streamline operations, though the final impact on share swap ratios and valuation should be reviewed once the scheme is finalized.
CRISIL Reaffirms Privi Speciality Chemicals' Ratings at AA-/Stable for Rs 1118 Cr Facilities
CRISIL Ratings has reaffirmed the long-term rating of 'CRISIL AA-/Stable' and the short-term rating of 'CRISIL A1+' for Privi Speciality Chemicals Limited. The rating covers total bank loan facilities amounting to Rs. 1,118 crore, which includes fund-based limits, non-fund based limits, and term loans. This reaffirmation reflects the company's maintained credit profile and its ability to service debt across its diverse banking consortium. The 'Stable' outlook indicates that the rating agency expects the company's business and financial risk profile to remain steady in the medium term.
முக்கிய அம்சங்கள்
Long-term credit rating reaffirmed at 'CRISIL AA-/Stable' for bank facilities.Short-term credit rating reaffirmed at 'CRISIL A1+', the highest rating for short-term debt.Total bank loan facilities rated amount to Rs. 1,118 crore across multiple major banks.Major term loan exposure includes Rs. 271 crore from HDFC Bank Limited.The ratings remain valid until March 31, 2027, subject to continuous surveillance.
👀 கவனிக்க வேண்டியவை
The reaffirmation confirms the company's stable financial health and consistent creditworthiness. Investors should view this as a sign of operational stability, though no immediate price action is expected from this routine update.
Privi Speciality Chemicals Invests ₹25.5 Cr in JV with Givaudan; Maintains 51% Stake
Privi Speciality Chemicals Limited has infused ₹25.5 crore into its joint venture company, Prigiv Specialties Private Limited, through a preferential allotment of equity shares. Its global partner, Givaudan SA of Switzerland, also contributed ₹24.5 crore, resulting in a total fresh capital infusion of ₹50 crore into the JV. Following this allotment, the total paid-up capital of the JV has increased to ₹85 crore. Privi Speciality Chemicals continues to hold a majority stake of 51%, while Givaudan holds the remaining 49%.
முக்கிய அம்சங்கள்
Privi Speciality Chemicals subscribed to 2.55 crore equity shares at ₹10 each, totaling ₹25.5 crore.JV partner Givaudan SA invested ₹24.5 crore for 2.45 crore shares to maintain its 49% stake.The total paid-up capital of Prigiv Specialties Private Limited rose from ₹35 crore to ₹85 crore.Privi Speciality Chemicals maintains controlling interest with a 51% shareholding post-allotment.
👀 கவனிக்க வேண்டியவை
Investors should view this capital infusion as a positive sign of commitment toward the strategic partnership with global leader Givaudan. This move strengthens the JV's balance sheet for future growth in the high-margin specialty chemicals space.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
